AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 51 min read

Guggenheim maintains Buy rating on Vaxcyte, $125 price target

Guggenheim kept its Buy rating on Vaxcyte with a $125 price target, implying a 121.3% upside from the Oct 2 close. The firm cited strong Phase 3 results for VAX-31, which surpassed expectations and showed superiority against key serotypes, suggesting a competitive advantage in the adult pneumococcal vaccine market.

Original reporting
tradingview.com
Published Oct 5, 2026, 12:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 12:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Guggenheim maintains Buy rating on Vaxcyte, $125 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

High
01

Why it matters

The Phase 3 OPUS‑1 trial met its primary endpoint and showed superiority over existing vaccines, prompting a target price increase.

02

Market read

The new data could catalyze a significant price move for VAXC and affect the broader vaccine sector.

03

What to watch

Regulatory timeline uncertainties and manufacturing scale‑up costs are not addressed in the note.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Vaxcyte is a clinical‑stage biotech developing adult pneumococcal conjugate vaccines.

Market effects

Sector

Strengthens the adult pneumococcal vaccine market outlook and may pressure peers.

Regional

Positive for US biotech sector and related healthcare indices.

Global

Potentially influences global vaccine competition and FDA pipeline expectations.

Counterpoint

What could challenge this read

If FDA raises concerns or requires additional data, the stock could face a sharp correction.

Key entities

  • analyst
    Guggenheim

    Equity research firm that upgraded Vaxcyte to Buy with a $125 price target.

  • company
    Vaxcyte

    Biotech firm developing VAX‑31 vaccine.

Read at source← All news

StoryVaxcyte reports positive Phase 3 data for VAX‑31, meeting all primary endpoints

Also covered by

4 outlets

Related articles

OCT 9
$PCVXHighAI 9/10

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

Vaxcyte (PCVX) closed public offerings raising $1.15B, including 8.58M shares at $64 each, pre-funded warrants, and $575M in convertible notes. Proceeds will fund clinical trials, manufacturing, and R&D. Joint bookrunners included Jefferies, Leerink, and BofA.

marketscreener.com2 min
OCT 9
$MRNAHighAI 8/10

A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally - Moderna (NASDAQ:MRNA), BioNTec

A new NIH initiative to accelerate personalized cancer vaccine development has sparked a rally in biotech stocks. Moderna, Novavax, BioNTech, Pfizer, Merck, and Vaxcyte saw gains. The program, launching in December, focuses on pancreatic, liver, colorectal cancers, and childhood tumors. Moderna and Merck reported positive Phase 3 results for their mRNA cancer vaccine in August. BioNTech is advancing multiple cancer therapies.

benzinga.com2 min